Triple Negative Breast Cancer Treatment Protocol

Triple Negative Breast Cancer Treatment Protocol

Triple negative breast cancer treatment protocol - In triple-negative breast cancer (TNBC), cancer cells do not contain receptors for estrogen, progesterone or HER2. This type of breast cancer is usually invasive and usually starts in breast channels. Healthy mammary cells contain receptors for estrogen and progesterone. They additionally contain receptors for a protein called HER2, which stimulates the normal growth of cells. About two out of three women with breast cancer have cells containing receptors for estrogen and progesterone and approximately 20-30% of breast cancer cases have too many HER2 receptors.

On these pages, you will read about metastatic triple negative breast cancer treatment options for stage 4, triple negative breast cancer treatment 2018, review, algorithm, challenges and solutions. In addition, you will read the new treatment for triple negative breast cancer and the answer to what is the best treatment for TNBC.

How are the treatment options for triple-negative breast cancer? Breast cancer that is a positive estrogen (ER) and the progesterone receptor (PR) can be treated with hormone therapy. Triple negative breast cancer treatment protocol - Breast cancer with HER2 excess can be treated with anti-HER2 drugs such as trastuzumab.

In women with triple-negative breast cancer, malignant cells do not contain receptors for estrogen, progesterone or HER2. ER, the PR and HER2 negative breast cancer may not be treated with hormonal therapy or medicines that act by HER2 blocking such as trastuzumab. Fortunately, triple-negative breast cancer can be treated with other medications such as chemotherapy, radiation therapy, and non-HER2 target therapy.

Triple Negative Breast Cancer Treatment Protocol

Triple Negative Organizations Breast Cancer Foundation uses the day to raise funds for their organizations. This means that women across the country should raise money for, in part, co-sponsored research by the Susan G. Komen Foundation, aimed at finding treatments targeted for the triple negative disease.

Of course, many important organizations, such as the TNBC Foundation, argue that "raising awareness" of breast cancer is their primary purpose today. I wonder how much awareness will take place? Or are these organizations just highlighting the same rhetoric that continues to create panic among innocent women about the third negative treatment option for breast cancer? It also means empowerment because here is the good news: if you have TNBC or are worried about it and you are open to exploring the evidence-based natural choices of medicines, there are many things you can do to Treat triple breast cancer three times.

Why does conventional treatment say TNBC so frightening? The TNBC Foundation site said: "TNBC tends to be more aggressive, more likely to relapse, and more difficult to treat because there is no targeted treatment." Triple negative breast cancer treatment protocol - This is in line with conventional thinking on the treatment of three types of negative breast cancer. Let's look ahead to see what they're really saying. See Also: Radiation For Breast Cancer Stage 1

First of all, Western medicine defines "treatment" For all types of cancer in just one of three ways: chemotherapy, radiation and/or surgery.

For women with TNBC, this could mean months of chemotherapy followed by a lumpectomy, followed by several weeks of toxic radiotherapy. The western drug says that TNBC is "Most treatable" in all cases of breast cancer because conventional treatments focus primarily on positive hormonal cancers. The conventional method of treating breast cancer focuses on the localization of sites hormone receptors. TNBC cells, on the other hand, do not have receptor sites for hormone progesterone or estrogen also did not interact with the HER2/neu protein.

With TNBC, there are no more treatments to "keep". Chemotherapy medications that use hormones such as tamoxifen, Arimidex (anastrozole), Aromasin (Exemestane), Femara (letrozole), or Faslodex (fulvestrant) will not work. Triple negative breast cancer treatment protocol - There will be no medicines affecting HER2/Neu proteins such as Herceptin (trastuzumab) or Tykerb (lapatinib).

This situation can be truly bleak for a woman who has TNBC and decides to go on a conventional path. The only way for him is a more intense chem, more weeks of radiation, and a more drastic surgical intervention. Of course, all this means more toxicity in the body, the immune system works much lower, and most likely increases the number of cancer stem cells of breast-cells that encourage cancer to begin.

Unfortunately, statistics confirm the danger of this breast cancer scenario. About 10-20% of all breast cancer diagnoses are "negative three ". Of these, the risk of recurrence of cancer in individuals TNBC higher in the first three years of conventional treatment compared to other forms of breast cancer. The overall survival rate is also lower. A study of 2007 more than 50,000 women found that those with TNBC who choose conventional treatment of cancer were 20% less likely to survive than women with other types of breast cancer who also chose, conventional treatment.

Triple Negative Breast Cancer Treatment Options

Triple negative breast cancer (TNBC) is composed of 15-20 percent of all breast cancer cases, but there are few treatment options beyond chemotherapy. This aggressive form of breast cancer disproportionately affects young women and women of African descent and is a breast cancer is most commonly diagnosed in women with BRCA1 mutations.

TNBC treatment is complicated by the inherent complexity of the disease. We know from a recent study that TNBC is not a disease but a group of diseases, each with a unique molecular profile that can suggest different potential therapies for each subtype of TNBC.

Triple negative breast cancer treatment protocol - In recent years, we have seen the emergence of new therapies for TNBC. This includes immunotherapy called immune examination inhibitors, drugs that target the androgen receptor, DNA agent destroyer, such as platinum medicines, conjugated antibodies to deliver drugs in cells have certain proteins on Its surface, a drug that blocks the path of DNA repair called PARP inhibitors, and approach combinations that are all tested in clinical trials.

Biopsy of triple fluid and breast cancer: The liquid biopsy appears as a non-invasive alternative for tissue biopsy to monitor the progression of the disease, the tumor response to treatment and even to predict the prognosis. These blood tests have the potential to change the way breast cancer is diagnosed and followed during treatment and recovery.

BCRF researchers have applied the tool in a variety of studies, including those focused on triple-negative breast cancer, to identify biomarkers. It can guide real-time treatment decisions that can save or prolong life.

Triple negative breast cancer treatment protocol - Two major studies published last year include: 1. in a study published last November, BCRF researchers used the data obtained from liquid biopsies to identify genetic markers to predict the results for three patients with negative breast cancer. And 2. Earlier this year, BCRF researchers used a liquid biopsy to analyze the DNA without cells (Cfdna originating) to identify patients with metastatic TNBC with an increased risk of dying of their disease. The study, published in the Journal of clinical oncology, also identifies a unique genetic change in cancer-related genes in MTNBC, compared to primary TNBC (pTNBC).